Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units ("RSUs") to four newly hired employees.
美国马萨诸塞州查尔斯顿，2024年6月4日 (环球新闻社) - 生命科学公司Solid Biosciences Inc. (纳斯达克股票代码: SLDB) (以下“公司”) 今天宣布，向四名新员工授予了30,949个受限制的股票单位 (RSUs)。
The RSUs vest in four equal installments on each one-year anniversary of the applicable employee's start date until the fourth anniversary of the applicable employee's start date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date.
这些RSUs每年分四个相等的部分解除锁定，并且直到适用员工的开始日期四周年之前才会解除锁定。获得股权奖励的实现取决于员工在每个适用解锁日期之前继续为公司服务。
These grants were made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
这些股票单位授予是根据公司的2024年诱因股票激励计划进行的，并作为该员工根据纳斯达克上市规则5635（c）（4）接受雇用的诱因。
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
关于固体生物科学（Solid Biosciences）
Solid Biosciences 是一家生命科学公司，专注于推进一系列基因治疗候选药物，包括用于治疗杜兴氏肌萎缩症 (Duchenne) 的 SGT-003、用于治疗儿茶酚胺多形性室性心动过速 (CPVT) 的 SGT-501、用于治疗BAG3介导的扩张型心肌病的AVB-401，以及其他用于治疗致命心脏病的资产。Solid正在推进其在罕见的神经肌肉和心脏疾病领域的各种管线，在科学、技术、疾病管理和护理方面汇集专家。以患者为中心，由直接受到影响的人创立，Solid的使命是改善患有这些毁灭性疾病的患者的日常生活。更多信息，请访问www.solidbio.com.
Solid Biosciences Investor Contact:
investors@solidbio.com
Solid Biosciences投资者联系方式：
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒体联系人：
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
来源：Solid Biosciences Inc.